Summary of H.B. Fuller Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: Up 5.8% year-on-year; organic revenue growth of 2.6% after adjusting for foreign exchange and acquisitions.

EBITDA: $181 million, a 9% increase year-on-year, with an EBITDA margin of 19.1%, up 70 basis points.

Earnings Per Share (EPS): Adjusted EPS rose 19% to $1.41.

Cash Flow: Cash flow from operations reached a record $121 million.

Net Debt to Adjusted EBITDA: Improved to 3.1 times, down from 3.4 times year-on-year.

2Strategic Updates and Business Highlights

Acquisition of Advanced Medical Solutions (AMS): H.B. Fuller announced an all-cash offer at GBP 2.85 per share, totaling approximately GBP 715 million. This acquisition is seen as a strategic fit to strengthen H.B. Fuller’s position in the medical adhesives market, which is expected to grow significantly.

Quantum Leap Initiative: The ongoing restructuring initiative is aimed at improving cost structure and cash flow, enhancing competitive positioning.

Segment Performance:

HHC: Organic revenue up 3%, with strong pricing execution leading to improved EBITDA margins.

EA: Organic revenue increased approximately 5% (excluding solar), driven by aerospace and electronics.

BAS: Organic sales up 6%, benefiting from strong demand in glass and infrastructure.

3Forward Guidance and Outlook

Fiscal 2026 Guidance:

Net revenue expected to rise mid-single digits; organic revenue projected to grow low single digits.

Adjusted EBITDA guidance revised to $650 million–$675 million; adjusted EPS expected in the range of $4.60–$4.90.

Cash flow from operations anticipated between $300 million–$325 million.

Q3 Expectations: Revenue expected to increase mid-single digits, with adjusted EBITDA in the range of $180 million–$190 million.

4Bad News, Challenges, or Points of Concern

Supply Chain Disruption: Ongoing disruptions in the petrochemical supply chain are expected to persist, impacting raw material costs and supply continuity.

Volume Declines: Slightly lower volumes year-on-year were noted, with expectations for mid-single-digit declines in the second half of the year, particularly in consumer-driven segments.

Market Reactions: The stock price fell approximately 8% following the acquisition announcement, indicating investor concerns regarding increased leverage and integration risks.

5Notable Q&A Insights

Investor Concerns: Questions arose regarding the characterization of H.B. Fuller post-acquisition and potential divestitures. Management reaffirmed their commitment to being a pure-play adhesives company.

Synergy Realization: Management indicated that the anticipated cost synergies from the AMS acquisition are higher than previous deals, with specific synergies from public company costs and operational efficiencies.

Volume Performance: The company noted that while volumes improved in Q2, they remain cautious about future demand, particularly in the consumer sector and automotive markets.

Regulatory and Market Barriers: The acquisition of AMS is expected to enhance H.B. Fuller's capabilities in navigating regulatory pathways and expanding into high-growth medical markets. This summary encapsulates the key financial metrics, strategic initiatives, outlook, challenges, and insights from the Q&A session, providing a comprehensive overview of H.B. Fuller's performance and future direction.